Last reviewed · How we verify
Mitomycin-C sponge
Mitomycin-C is an antibiotic that alkylates DNA, causing cross-linking and cell death, used topically to prevent scar tissue formation after ocular surgery.
Mitomycin-C is an antibiotic that alkylates DNA, causing cross-linking and cell death, delivered via a biodegradable sponge for localized tissue application. Used for Prevention of conjunctival scarring and fibrosis following ocular surgery, Adjunctive therapy in glaucoma filtration surgery, Prevention of pterygium recurrence.
At a glance
| Generic name | Mitomycin-C sponge |
|---|---|
| Sponsor | University of California, San Diego |
| Drug class | Alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology; Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Mitomycin-C is a mitomycin antibiotic that acts as a DNA alkylating agent, creating interstrand cross-links that prevent DNA replication and transcription, leading to cell death. When delivered via a sponge formulation during ophthalmic surgery, it inhibits fibroblast proliferation and collagen deposition, thereby reducing postoperative scarring and improving surgical outcomes in procedures like glaucoma filtration surgery and corneal transplantation.
Approved indications
- Prevention of postoperative scarring in glaucoma filtration surgery
- Prevention of scarring in corneal transplantation and refractive surgery
Common side effects
- Corneal toxicity / epithelial defects
- Hypotony (low intraocular pressure)
- Cataract formation
- Endothelial cell loss
Key clinical trials
- Conventional Non-Penetrating Deep Sclerectomy Versus Modified Subflap Mattress Suture in OAG (NA)
- CsA vs MMC for Preventing Pterygium Recurrence (NA)
- Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
- Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy (PHASE4)
- Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy. (EARLY_PHASE1)
- Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia (NA)
- Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver (PHASE2)
- InnFocus MicroShunt Versus Trabeculectomy Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitomycin-C sponge CI brief — competitive landscape report
- Mitomycin-C sponge updates RSS · CI watch RSS
- University of California, San Diego portfolio CI